Second Sight Medical Products Inc
EYESW · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $5 | $5 | $4 | $15 |
| G&A Expenses | $2 | $3 | $2 | $7 |
| SG&A Expenses | $2 | $3 | $2 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $7 | $7 | $22 |
| Operating Income | -$7 | -$7 | -$7 | -$22 |
| % Margin | – | – | – | 8,337,722.7% |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$7 | -$7 | -$6 | -$20 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$7 | -$7 | -$6 | -$20 |
| % Margin | – | – | – | 7,876,568.8% |
| EPS | -0.11 | -0.12 | -0.11 | -0.35 |
| % Growth | 8.3% | -9.1% | 68.6% | – |
| EPS Diluted | -0.11 | -0.12 | -0.11 | -0.35 |
| Weighted Avg Shares Out | 60 | 59 | 59 | 55 |
| Weighted Avg Shares Out Dil | 60 | 59 | 59 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$7 | -$7 | -$7 | -$19 |
| % Margin | – | – | – | 7,412,370.4% |